Xiuting Lin

发表

A phase 1 trial to determine the maximum tolerated dose and patient-specific dosimetry of [177Lu]Lu-LNC1003 in patients with metastatic castration-resistant prostate cancer.

Wei-bing Miao, Huipan Liu, Haojun Chen, 2023, European journal of nuclear medicine and molecular imaging.